D313Y Variant in Fabry Disease
Authors:
- Lina PalaiodimouLPLina Palaiodimou
- Maria-Ioanna StefanouMSMaria-Ioanna Stefanou
- Eleni BakolaEBEleni Bakola
- Marianna PapadopoulouMPMarianna Papadopoulou
- Panagiotis KokotisPKPanagiotis Kokotis
- Agathi-Rosa VrettouAVAgathi-Rosa Vrettou
- Eleni KapsiaEKEleni Kapsia
- Dimitrios PetrasDPDimitrios Petras
- Aris AnastasakisAAAris Anastasakis
- Nikolaos XifarasNXNikolaos Xifaras
- Eleni KarachaliouEKEleni Karachaliou
- Giota TouloumiGTGiota Touloumi
- 8 November 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (19) , E2188-E2200
Abstract
Background and Objectives There is accumulating evidence in the literature indicating a strong correlation between Fabry disease (FD) phenotypes and specific sequence variations in the Galactosidase Alpha (GLA) gene. Among them, the potential pathogenicity and clinical relevance of D313Y variation in patients with FD remain debated. Methods We performed a systematic review andmeta-analysis of studies reporting D313Y as single occurring variant in the GLA gene and sought to evaluate (1) the prevalence of D313Y variation in different populations with or without clinical manifestations of FD, (2) the clinical FD phenotype in D313Y-positive patients, and (3) the proportion of D313Y-positive patients presenting abnormal laboratory findings (alpha-galactosidase-A deficiency or globotriaosylceramide accumulation). Results Forty cohorts comprising 211 individuals with D313Y variation among 42,723 participants with available GLA gene-sequencing data were included. Patients highly suspected for FD had a higher prevalence of D313Y variation (4.9%, 95% CI 1.6%-9.9%; I-2 = 95.5%) compared with the general population (0%, 95% CI 0%-0.1%; I-2 = 1.9%; p = 0.004). The prevalence of D313Y variation was 0.6% (95% CI 0.3%-1%; I-2 = 74.1%), 0.4% (95% CI 0.2%-0.7%; I-2 = 0%), and 0.3% (95% CI 0.2%-0.4%; I-2 = 0%) in patients presenting with neurologic, cardiac, or renal manifestations, respectively. D313Y was associated with a milder, late-onset FD phenotype, as indicated by the mean patient age of 51 years (95% CI 44-59; I-2 = 94%) and the evidence of alpha-galactosidase A deficiency and globotriaosylceramide accumulation in 26.7% (95% CI 15.3%-40%; I-2= 34%) and 16.2% (95% CI 8%-26.4%; I2 = 35%) of cases, respectively. D313Y-positive patients displayed predominantly neurologic FD manifestations (58.1%, 95% CI 37.7%-77.1%; I-2= 78%), with central and peripheral nervous system (CNS/PNS) involvement noted in 28.2% (95% CI 15.4%-43.2%; I-2 = 51%) and 28.5% (95% CI 17.8%-40.5%; I-2 = 61%) of cases, respectively. Discussion D313Y variation seems to correlate with an atypical, mild late-onset phenotype with predominantly neurologic FD manifestations. Monitoring for CNS/PNS involvement is thus paramount to identify D313Y-positive patients with latent or early-FD pathology, which may qualify for enzyme-replacement therapy or chaperone treatment.Keywords
This publication has 46 references indexed in Scilit:
- Acute Cerebrovascular Disease in the YoungStroke, 2013
- Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry diseaseJournal of Human Genetics, 2011
- On the role of autophagy in human diseases: a gender perspectiveJournal of Cellular and Molecular Medicine, 2011
- Fabry disease in patients with migraine with auraNeurological Sciences, 2010
- Belgian Fabry StudyStroke, 2010
- Mutations of the GLA Gene in Young Patients With StrokeStroke, 2010
- Frequency of Fabry disease in male and female haemodialysis patients in SpainBMC Medical Genetics, 2010
- Frequency of Unrecognized Fabry Disease Among Young European-American and African-American Men With First Ischemic StrokeStroke, 2010
- Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic CardiomyopathyJACC, 2007
- Fabry disease: Characterization of ?-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency alleleHuman Mutation, 2003